Inactive Instrument

News CymaBay Therapeutics, Inc.

Equities

CBAY

US23257D1037

Delayed Nasdaq Other stock markets 04:00:00 2024-03-21 pm EDT			5-day change	1st Jan Change
32.48 ^USD	+0.03%		-.--%	+37.51%

Mar. 22	Gilead Sciences Completes $4.3 Billion Cymabay Acquisition	MT
Mar. 22	CymaBay Therapeutics, Inc. Announces Board Changes	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Gilead Sciences Announces Completion of Acquisition of CymaBay	Mar. 25	AQ
Gilead Sciences Completes $4.3 Billion Cymabay Acquisition	Mar. 22	MT
CymaBay Therapeutics : Acquisition/Asset Disposal - Form 8-K	Mar. 22	PU
CymaBay Therapeutics, Inc. Announces Board Changes	Mar. 22	CI
CymaBay Therapeutics, Inc.(NasdaqGS:CBAY) dropped from NASDAQ Composite Index	Mar. 21	CI
Gilead Sciences, Inc. completed the acquisition of CymaBay Therapeutics, Inc..	Mar. 21	CI
CymaBay Therapeutics, Inc.(NasdaqGS:CBAY) dropped from S&P Pharmaceuticals Select Industry Index	Mar. 21	CI
CymaBay Therapeutics, Inc.(NasdaqGS:CBAY) dropped from S&P TMI Index	Mar. 21	CI
CymaBay Therapeutics, Inc.(NasdaqGS:CBAY) dropped from S&P Global BMI Index	Mar. 21	CI
CymaBay Therapeutics, Inc.(NasdaqGS:CBAY) dropped from NASDAQ Biotechnology Index	Mar. 14	CI
Gilead Sciences Says Antitrust Waiting Period for CymaBay Therapeutics Deal Expires	Mar. 11	MT
CymaBay Says European Medicines Agency to Review Marketing Authorization Application for Seladelpar	Mar. 04	MT
CymaBay Announces European Medicines Agency Accepts for Review the Marketing Authorization Application for Seladelpar for the Treatment of Primary Biliary Cholangitis	Mar. 04	AQ
CymaBay Therapeutics, Inc. Announces European Medicines Agency Accepts for Review the Marketing Authorization Application for Seladelpar for the Treatment of Primary Biliary Cholangitis	Mar. 04	CI
CymaBay Reports Fourth Quarter and Year Ended December 31, 2023 Financial Results and Provides Corporate Update	Feb. 28	AQ
CymaBay Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 28	CI
CymaBay Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 28	CI
CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)	Feb. 21	AQ
CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	Feb. 20	AQ
Leerink Partners Downgrades CymaBay Therapeutics to Market Perform From Outperform, Adjusts PT to $32.50 From $26	Feb. 20	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News CymaBay Therapeutics, Inc.

Equities

CBAY

US23257D1037

Summary

Filters